Peritoneal metastases of lower gastrointestinal tract origin: A comparative study of patient outcomes following cytoreduction and intraperitoneal chemotherapy

Journal of Cancer Research and Clinical Oncology

Volumn 139, Issue 11, 2013, Pages 1899-1908

  Ung, Lawson ^a,b   C Chua, Terence ^a,b   L Morris, David ^a,b  

^a ST GEORGE HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Colorectal cancer; Cytoreductive surgery; Intraperitoneal chemotherapy; Metastatic colorectal cancer; Peritoneal metastases

Indexed keywords

FLUOROURACIL;

ADULT; AGED; APPENDIX CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; COLON CANCER; COMPARATIVE STUDY; CYTOREDUCTIVE SURGERY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; INTRAPERITONEAL CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERITONEUM METASTASIS; PRIMARY TUMOR; PRIORITY JOURNAL; RECTUM CANCER; TREATMENT OUTCOME; ADENOCARCINOMA; APPENDICEAL NEOPLASMS; COLONIC NEOPLASMS; INTESTINAL NEOPLASMS; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PERITONEAL NEOPLASMS; RECTAL NEOPLASMS; RETROSPECTIVE STUDY; SECONDARY; SURVIVAL RATE;

ADENOCARCINOMA; AGED; APPENDICEAL NEOPLASMS; COLONIC NEOPLASMS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INTESTINAL NEOPLASMS; MALE; MIDDLE AGED; PERITONEAL NEOPLASMS; RECTAL NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84892675272     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-013-1517-y     Document Type: Article

References (26)

1. Bokemeyer C, Van Cutsem E, Rougier P, Ciardiello F, Heeger S, Schlichting M, Celik I, Kohne CH (2012) Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer (Oxford, England: 1990) 48(10):1466-1475. doi:10.1016/j.ejca.2012.02. 057
2. Cao C, Yan TD, Black D, Morris DL (2009) A systematic review and meta-analysis of cytoreductive surgery with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol 16(8):2152-2165. doi:10.1245/ s10434-009-0487-4
3. Cao C, Yan TD, Deraco M, Elias D, Glehen O, Levine EA, Moran BJ, Morris DL, Chua TC, Piso P, Sugarbaker PH, Peritoneal Surface Malignancy G (2012) Importance of gender in diffuse malignant peritoneal mesothelioma. Ann Oncol 23(6):1494-1498. doi:10. 1093/annonc/mdr477
4. Carr NJ, Emory TS, Sobin LH (2002) Epithelial neoplasms of the appendix and colorectum: an analysis of cell proliferation, apoptosis, and expression of p53, CD44, bcl-2. Arch Pathol Lab Med 126(7):837-841. doi:10.1043/0003- 9985(2002)126\0837: enotaa[2.0.co;2
5. Chua TC, Yao P, Akther J, Young L, Bao S, Samaraweera U, Yan TD, Morris DL (2009) Differential expression of Ki-67 and sex steroid hormone receptors between genders in peritoneal mesothelioma. Pathol Oncol Res 15(4):671-678. doi:10.1007/s12253-009-9170-0
6. Chua TC, Pelz JO, Morris DL (2012a) Surgery for colorectal peritoneal carcinomatosis. Scand J Gastroenterol 47(3):277-285. doi:10.3109/00365521.2012. 640825
7. Chua TC, Moran BJ, Sugarbaker PH, Levine EA, Glehen O, Gilly FN, Baratti D, Deraco M, Elias D, Sardi A, Liauw W, Yan TD, Barrios P, Gomez Portilla A, de Hingh IH, Ceelen WP, Pelz JO, Piso P, Gonzalez-Moreno S, Van Der Speeten K, Morris DL (2012b) Early-and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol 30(20):2449-2456. doi:10. 1200/jco.2011.39.7166
8. Colucci G, Gebbia V, Paoletti G, Giuliani F, Caruso M, Gebbia N, Carteni G, Agostara B, Pezzella G, Manzione L, Borsellino N, Misino A, Romito S, Durini E, Cordio S, Di Seri M, Lopez M, Maiello E, Montemurro S, Cramarossa A, Lorusso V, Di Bisceglie M, Chiarenza M, Valerio MR, Guida T, Leonardi V, Pisconti S, Rosati G, Carrozza F, Nettis G, Valdesi M, Filippelli G, Fortunato S, Mancarella S, Brunetti C, Gruppo Oncologico Dell'Italia M (2005) Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 23(22):4866-4875. doi:10.1200/jco. 2005.07.113
9. Diaz-Rubio E, Tabernero J, Gomez-Espana A, Massuti B, Sastre J, Chaves M, Abad A, Carrato A, Queralt B, Reina JJ, Maurel J, Gonzalez-Flores E, Aparicio J, Rivera F, Losa F, Aranda E, Spanish Cooperative Group for the Treatment of Digestive Tumors T (2007) Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. J Clin Oncol 25(27):4224-4230. doi:10.1200/jco. 2006.09.8467
10. Elias D, Glehen O, Pocard M, Quenet F, Goere D, Arvieux C, Rat P, Gilly F, Association Française de Chirurgie (2010) A comparative study of complete cytoreductive surgery plus intraperitoneal chemotherapy to treat peritoneal dissemination from colon, rectum, small bowel, and nonpseudomyxoma appendix. Ann Surg 251(5):896-901. doi:10.1097/SLA.0b013e3181d9765d
11. Franko J, Shi Q, Goldman CD, Pockaj BA, Nelson GD, Goldberg RM, Pitot HC, Grothey A, Alberts SR, Sargent DJ (2012) Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol 30(3):263-267. doi:10.1200/jco.2011.37.1039
12. Fuchs CS, Marshall J, Mitchell E, Wierzbicki R, Ganju V, Jeffery M, Schulz J, Richards D, Soufi-Mahjoubi R, Wang B, Barrueco J (2007) Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 25(30):4779-4786. doi:10.1200/ jco.2007.11.3357
13. Fuchs CS, Marshall J, Barrueco J (2008) Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study. J Clin Oncol 26(4):689-690. doi:10.1200/jco.2007.15.5390
14. Glehen O, Kwiatkowski F, Sugarbaker P, Elias D, Levine E, De Simone M, Barone R, Yonemura Y, Cavaliere F, Quenet F (2004) Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol 22(16):3284-3292
15. Glehen O, Gilly FN, Boutitie F, Bereder JM, Quenet F, Sideris L, Mansvelt B, Lorimier G, Msika S, Elias D, French Surgical A (2010) Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1,290 patients. Cancer 116(24):5608-5618. doi:10. 1002/cncr.25356
16. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New Eng J Med 350(23):2335-2342. doi:10. 1056/NEJMoa032691
17. Lieu CH, Lambert LA, Wolff RA, Eng C, Zhang N, Wen S, Rafeeq S, Taggart M, Fournier K, Royal R, Mansfield P, Overman MJ (2012) Systemic chemotherapy and surgical cytoreduction for poorly differentiated and signet ring cell adenocarcinomas of the appendix. Ann Oncol 23(3):652-658. doi:10.1093/annonc/ mdr279
18. National Cancer Institute (1999) National Cancer Institute Common Toxicity Criteria Version 2
19. Porschen R, Arkenau HT, Kubicka S, Greil R, Seufferlein T, Freier W, Kretzschmar A, Graeven U, Grothey A, Hinke A, Schmiegel W, Schmoll HJ, Group AIOCS (2007) Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. J Clin Oncol 25(27):4217-4223. doi:10.1200/jco.2006.09.2684
20. Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J, Fontaumard E, Brachet A, Caillot JL, Faure JL, Porcheron J, Peix JL, Francois Y, Vignal J, Gilly FN (2000) Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer 88(2):358-363
21. Sugarbaker PH (1998) Intraperitoneal chemotherapy and cytoreductive surgery for the prevention and treatment of peritoneal carcinomatosis and sarcomatosis. Semin Surg Oncol 14(3): 254-261
22. Sugarbaker PH (2005) Surgical management of carcinomatosis from colorectal cancer. Clin Colon Rectal Surg 18(3):190-203. doi:10.1055/s-2005- 916280
23. Sugarbaker PH (2009) Epithelial appendiceal neoplasms. Can J (Sudbury, Mass) 15(3):225-235. doi:10.1097/PPO.0b013e 3181a9c781
24. Sugarbaker PH, Jablonski KA (1995) Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. Ann Surg 221(2):124-132
25. Van Cutsem E, Lang I, Folprecht G, Nowacki M, Barone C, Shchepotin I, Maurel J, Cunningham D, Celik I, Kohne C (2010) Cetuximab plus FOLFIRI: final data from the CRYSTAL study on the association of KRAS and BRAF biomarker status with treatment outcome. J Clin Oncol 28 (15S):3570
26. Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, Zoetmulder FA (2003) Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 21(20):3737-3743. doi:10.1200/jco.2003.04.187